| |
Wednesday, February 26, 2025 | 12pm ET / 9am PT In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome overcome these challenges using AI cloud infrastructure and advanced machine learning tools. 
|
|
Today’s Big NewsFeb 4, 2025 |
|
Wednesday, February 26, 2025 | 11am ET / 8am PT Discover how the convergence of spatial biology, AI, and computational tools is transforming cancer research. This webinar explores high-multiplex spatial analysis, tumor heterogeneity, and advances in precision medicine, reshaping drug development. Register now to learn how these innovations are driving breakthroughs in oncology. 
|
|
| By Angus Liu As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in its home state of New Jersey. |
|
|
|
By Nick Paul Taylor Pfizer tallied up $1.2 billion in impairment charges in response to changes in development plans and commercial forecasts for Seagen-acquired ADCs. |
By Conor Hale Shortly after the Trump administration imposed new tariffs on China, the country responded with levies of its own—and placed Illumina on a government watchlist. |
By Nick Paul Taylor For the fourth time in five months, the PMCPA has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest telling-off after the U.K. drug marketing watchdog reviewed social media posts and other materials related to the NextCOVE clinical trial of its COVID-19 vaccine. |
|
Thursday, February 27, 2025 | 2pm ET / 11am PT The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights. 
|
|
By Fraiser Kansteiner The recent decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is suspending shipments to the world’s second-most populous country. |
By James Waldron Astellas is preparing a significant shake-up of its top tier roles, including ushering out its current Chief Scientific Officer and Chief Manufacturing Officer. |
By Eric Sagonowsky HHS secretary nominee Robert F. Kennedy Jr. is one step closer to confirmation as the Senate Finance Committee voted on Tuesday to advance his nomination for a full Senate vote. |
By Andrea Park In 2000, the Union for International Cancer Control named Feb. 4 World Cancer Day, with a goal of raising awareness of cancer and encouraging efforts to prevent and treat its various forms. A quarter-century later, the initiative is still going strong, with biopharma organizations joining countless other companies and individuals in the battle against what the UICC describes as “the global cancer epidemic.” |
By Fraiser Kansteiner Manufacturing firm Jabil has purchased Maryland-based CDMO Pharmaceutics International for an undisclosed sum. The deal, which closed Monday, immediately arms Jabil with contracting firepower in aseptic filling and freeze drying services, as well as oral solid dose production across multiple stages of product development. |
By James Waldron Four months after laying off 60% of its workforce, Turnstone Biologics is planning further redundancies as the biotech gives up on its last remaining clinical-stage candidate over manufacturing costs. |
By Kevin Dunleavy Regeneron's PD-1 cancer treatment Libtayo, which continues to exceed analyst expectations, has become a blockbuster for the first time. After the drug delivered $1.22 billion in sales last year, the company says there's room for more growth. |
By Gabrielle Masson Valerio Therapeutics is ending all clinical trials, including an ongoing phase 1/2 study for its investigational “DNA decoy” candidate designed to treat recurrent solid tumor cancers. |
By Conor Hale According to Roche, the diagnostic’s expansion into the ultralow category may allow between 20% to 25% of patients whose breast tumors were previously labeled as HR-positive and HER2-negative to become candidates for the targeted therapy. |
By Andrea Park Arcutis Biotherapeutics is going long with the latest push for its seborrheic dermatitis treatment Zoryve. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025. |
|
|---|
|
|
Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
